MAP Pharmaceuticals Submits New Drug Application to FDA for Levadex Orally Inhaled Migraine Drug
Links shared publicly online about this topic.
- 252total visits
MAP Pharmaceuticals Submits New Drug Application to FDA for Levadex Orally Inhaled Migraine Drug
Levadex (dihydroergotamine) is a new drug in development for the acute treatment of migraine. Levadex information includes news, clinical trial results and side effects.
View full resource at drugs.com
Tags: Migraine, Migraine Medication, Headache, Vascular Headache, Drug, Pharma, FDA
Most Recently Shared on June 1, 2011 at 12:10 am By:
MAP Pharmaceuticals Submits New Drug Application to FDA for Levadex Orally Inhaled Migraine Drug: MOUNTAIN... http://bit.ly/kY3fZf #drug
MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults
news-medical.net — “MAP Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults.” View full resource at news-medical.net
Most Recently Shared on May 27, 2011 at 5:38 am By:
MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults: MAP Pharmaceuticals, Inc. to... http://bit.ly/iwytro
Advertisement
